
Claims:

1. A compound having the formula M-L-D wherein M is a mannose moiety, L is a linker moiety and D is a drug moiety, wherein the drug moiety is a corticosteroid.
2. The compound according to claim 1 wherein L is a linker comprises a hydrazone moiety, an oxime moiety, an imine moiety, and a thioether moiety.
3. The compound according to claim 1 or 2 wherein L further comprises a carbonyl group.
4. The compound according to claim 3 wherein the carbonyl group is bound to the hydrazone moiety.
5. The compound according to claim 2 wherein L is a linker comprising an oxime moiety.
6. The compound according to any one of the previous claims where L further comprises a C1-C12 alkyl group.
7. The compound according to claim 6 wherein the C1-C12 alkyl group is bound to the carbonyl group.
8. The compound according to any one of claims 6 or 7 wherein the alkyl group is a C1-C6 alkyl group.
9. The compound according to any one of the previous claims wherein the steroid is selected from the group consisting of: prednisone, dexamethasone, betamethasone, prednisolone, triamcinolone, hydrocortisone, fludrocortisone, and methylprednisolone.
10. The compound according to claim 9 wherein the drug is prednisone or dexamethasone.

~~11.~~1. A compound according to the formula:



wherein R_1 is a direct bond; or C1-C12 straight alkyl or branched alkyl;

R_2 is hydrogen or fluorine;

R_3 is a hydrogen or methyl group.

R_4 is a hydroxyl group or a ketone group.

~~12.~~2. The compound according to claim ~~11~~ 1 wherein R_1 is a direct bond.

~~13.~~3. The compound according to claim ~~11~~ 1 wherein R_1 is a CH_2 group.


~~14.~~4. The compound according to claim ~~11~~ 1 wherein R_1 is (methyl)ethyl group.

~~15.~~5. The compound according to claim ~~11~~ 1 wherein R_1 is a pentyl group.

~~16.~~6. The compound according to any one of claims ~~11~~ 1 to ~~15~~ 5 wherein R_2 and R_3 are H and R_4 is a ketone group.

~~17.~~7. The compound according to any one of claims ~~11~~ 1 to ~~15~~ 5 wherein R_2 is fluorine, R_3 is methyl and R_4 is a hydroxyl group.

~~18.~~8. A compound according to the formula:



wherein R_1 is a direct bond; or C1-C12 straight alkyl or branched alkyl;

R_2 is hydrogen or fluorine;

R_3 is a hydrogen or methyl group; and

R_4 is a hydroxyl group or a ketone group.

~~19.~~9. The compound according to claim ~~18~~ 8 wherein R_1 is a $(CH_2)_3$ group.

~~20.~~10. The compound according to either one of claims ~~18~~ 8 or ~~19~~ 9 wherein R_2 and R_3 are H and R_4 is a ketone group.

~~21.~~11. The compound according to either one of claims ~~18~~ 8 or ~~19~~ 9 wherein R_2 is fluorine, R_3 is methyl and R_4 is a hydroxyl group.

~~22. A pharmaceutical composition comprising a compound according to any one of the previous claims.~~

~~23. A method for treatment of a disease comprising administering to a patient in need thereof a compound according to any one of claims 1 to 21.~~

~~24. The method according to claim 23 wherein the disease is associated with increased macrophage activation.~~

~~25. The method according to claim 24 wherein the disease is an autoimmune disease or an inflammatory disease.~~

~~26. The method according to claim 25 wherein the disease is selected from the group consisting of: rheumatoid arthritis, autoimmune enteropathy, psoriasis, dermatitis, alopecia, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome and autoimmune endocrinopathies.~~

~~27. The method according to claim 24 wherein the disease is non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.~~

28. The method according to claim 24 wherein the disease is a neuroinflammatory disease.

29. The method according to claim 28 wherein the neuroinflammatory disease is selected from the group consisting of: multiple sclerosis, neuromyelitis optica, optic neuritis, Alzheimer's disease and transverse myelitis.

30. The method according to claim 24 wherein the disease is Parkinson's disease.

31. The method according to claim 24 wherein the disease is a lipid storage disease.

32. The method according to claim 31 wherein the disease is selected from the group consisting of: Gaucher's disease, Niemann-Pick disease, Fabry's disease, Farber's disease and Tay-Sachs.

33. The method according to claim 24 wherein the disease is asthma.

34. The method according to claim 24 wherein the disease is selected from the group consisting of: depression, drug addiction, and opioid addiction.

35. The method according to claim 24 wherein the disease is selected from the group consisting of: atherosclerosis and cardiovascular disease.

36. The method according to claim 24 wherein the disease is a pathogen, comprising a viral disease, a bacterial disease or a protozoan disease.

37. The method according to claim 36 wherein the disease is resultant from a coronavirus infection.

38. The method according to claim 37 wherein the disease is COVID-19.

39. The method according to claim 38 wherein the patient does not have COVID-19 symptoms.

40. The method according to claim 36 wherein the disease is leishmaniasis.

41. The method according to claim 24 wherein the patient is suffering from cytokine release syndrome.

42. The method according to any one of claims 23 to 42 wherein the patient is also suffering form a disease associated with a metabolic disorder associated with glucose metabolism.

43. The method according to claim 42 wherein the metabolic disorder is diabetes or metabolic syndrome.

44. A method for treatment of an inflammatory or autoimmune disease by selectively delivering a corticosteroid to an immune cell.

45. The method according to claim 44, wherein the immune cell is a macrophage.

~~46. The method according to claim 44 or 45 comprising administering a compound according to any one of claims 1 to 21.~~

~~47. The method according to claim 23 wherein the disease is a disease of the brain.~~

~~48. The method according to claim 47 wherein the disease is a neurological disease.~~

~~49. The method according to claim 48 wherein the disease is a cancer of the brain.~~

~~50. The method according to claim 49 wherein the disease is glioblastoma.~~

~~51. A compound according to any one of claims 1-21 wherein the compound has a molecular weight of less than 800.~~